$2.54
5.93% yesterday
Nasdaq, Jun 12, 10:13 pm CET
ISIN
US7995661045
Symbol
SANA
Sector
Industry

Sana Biotechnology Inc Stock price

$2.54
+0.54 27.00% 1M
+0.50 24.51% 6M
+0.91 55.83% YTD
-4.28 62.76% 1Y
-32.56 92.76% 5Y
-32.56 92.76% 10Y
-32.56 92.76% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.16 5.93%
ISIN
US7995661045
Symbol
SANA
Sector
Industry

Key metrics

Market capitalization $572.91m
Enterprise Value $468.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.74
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-212.63m
Free Cash Flow (TTM) Free Cash Flow $-223.90m
Cash position $104.70m
EPS (TTM) EPS $-0.88
P/E forward negative
Short interest 77.80%
Show more

Is Sana Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Sana Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Sana Biotechnology Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Sana Biotechnology Inc forecast:

Buy
88%
Hold
13%

Financial data from Sana Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 59 59
19% 19%
-
- Research and Development Expense 198 198
23% 23%
-
-195 -195
34% 34%
-
- Depreciation and Amortization 17 17
28% 28%
-
EBIT (Operating Income) EBIT -213 -213
34% 34%
-
Net Profit -209 -209
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Sana Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sana Biotechnology Inc Stock News

Neutral
GlobeNewsWire
4 days ago
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes
Neutral
GlobeNewsWire
16 days ago
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update.
Neutral
Seeking Alpha
25 days ago
Data from phase 1 studies using SC291 to treat patients with B-cell mediated autoimmune disorders and SC262 for patients with relapsed/refractory B-cell malignancies expected in 2025. First-in-human study using UP421 as a HIP-modified primary islet cell therapy to treat patients with Type 1 Diabetes established increase circulating C-peptide biomarker and without need of immunosuppressive thera...
More Sana Biotechnology Inc News

Company Profile

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses in identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 13, 2018 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Harr
Employees 328
Founded 2018
Website sana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today